The NCCN Guidelines for Ovarian Cancer include recommendations for a broad range of histologic subtypes of this malignancy, and recommendations for use of oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. As maintenance therapy in select patients with recurrent, platinum-sensitive, chemotherapy-responsive disease, PARP inhibitors were shown to improve progression-free survival (PFS) for patients with BRCA-mutant and BRCA wild-type disease, indicating that these agents are potentially beneficial to many patients with platinum-sensitive disease in this setting, according to Deborah K. Armstrong, MD, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Director of the Johns Hopkins Breast and Ovarian Cancer Screening Service; and Chair of the NCCN Guidelines Panel for Ovarian Cancer.
“The first time we included information about histology was in 2017, so this topic is still new. PARP inhibitors represent an explosion in the world of ovarian cancer, and they have been included in the guidelines since 2016. Now, we list 3 in the [NCCN] Compendia, and we are also emphasizing their use as maintenance therapy,” Dr. Armstrong said as she described this malignancy at the NCCN 23rd Annual Conference.
Dr. Armstrong has disclosed that she has served as a scientific advisor for Morphotek Inc., and has received grant/research support from Advaxis, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Pfizer Inc., Syndax, and Tesaro, Inc., and that her spouse or significant other has received grant/research support from Eisai Inc. and Exelixis Inc.
Gelmon KA, Tischkowitz M, Mackay H. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852–861.
Domchek SM, Aghajanian C, Shapira-Frommer R. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016;140:199–203.
Swisher EM, Lin KK, Oza AM. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75–87.
Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382–1392.
Mirza MR, Monk BJ, Herrstedt J. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.